Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Recently announced acquisition of assets of Heron Therapeutics —— Q3 2026 consolidated revenue of $54.5 million —— Q3 2026 net loss of $14.7 million; Adjusted EBITDA of $3.1 million —— Company maintains FY 2026 revenue and narrows Adjusted EBITDA guidance —— Conference call scheduled for today at…